ロード中...

FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation

Tyrosine kinase inhibitors (TKIs) targeting FLT3 have shown activity but when used alone have achieved limited success in clinical trials, suggesting the need for combination with other drugs. We investigated the combination of FLT3 TKIs (Gilteritinib or Sorafenib), with Venetoclax, a BCL-2 selectiv...

詳細記述

保存先:
書誌詳細
出版年:Signal Transduct Target Ther
主要な著者: Zhu, Ruiqi, Li, Li, Nguyen, Bao, Seo, Jaesung, Wu, Min, Seale, Tessa, Levis, Mark, Duffield, Amy, Hu, Yu, Small, Donald
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group UK 2021
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8141515/
https://ncbi.nlm.nih.gov/pubmed/34024909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41392-021-00578-4
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!